Compare Kyndryl Holdings Inc (KD) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 22.7× Kyndryl Holdings Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| KD | TAK | |
|---|---|---|
Market Cap | $2.59B | $58.74B |
Volume | 5,354,348 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $29.76 | $19.05 |
52-Week Low | $10.59 | $13.23 |
Typical Hold Time | 36 Days | 1 Days |
Enterprise Value | $5.41B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.75, up 2.62% with bearish technical signals but improving fundamentals. The company reported positive net income of $252M in 2025 after years of losses, with revenue stabilizing around $15B. Recent news highlights AI initiatives including a new Dallas innovation lab and healthcare IT acquisition. Analyst consensus is mixed with 71% hold ratings but a $14.67 price target suggesting 25% upside potential.
KD shows fundamental improvement with profitability returning, though earnings misses and competitive pressures remain risks. The stock trades at reasonable valuations (P/S 0.18x) but faces execution challenges in its AI transformation. Institutional interest is building with recent purchases, but technical weakness suggests near-term consolidation likely before sustained upward movement.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
